Asset Details
Do you wish to reserve the book?
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Do you wish to request the book?
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
2011
Overview
Ipilimumab has been shown to improve survival in patients with previously treated metastatic melanoma. In this study, ipilimumab plus dacarbazine improved survival in patients with previously untreated metastatic melanoma.
The survival rate for patients with metastatic melanoma is low, with an expected 2-year survival rate of 10 to 20%.
1
–
3
Although dacarbazine has never been shown to improve survival in randomized, controlled studies, it has been the drug most frequently compared with new agents or combination therapies in randomized trials involving patients with melanoma.
4
,
5
High-dose interleukin-2 is associated with durable, complete responses, with a survival benefit, in a small subgroup of patients with metastatic melanoma.
6
,
7
Ipilimumab, a fully human, IgG1 monoclonal antibody, blocks cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), a negative regulator of T cells, and thereby augments . . .
Publisher
Massachusetts Medical Society
Subject
Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antineoplastic Agents, Alkylating - administration & dosage
/ Antineoplastic Agents, Alkylating - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Dacarbazine - administration & dosage
/ Dacarbazine - adverse effects
/ Female
/ Humans
/ Liver
/ Male
/ Melanoma
/ Patients
/ Survival
